DNTH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

398.09K

-69.96%

-1.078

+33.14%

199.43K

-82.85%

-0.906

+10.52%

213.71K

+10.73%

-0.926

+5.26%

Estimates Revision

The market is revising Downward the revenue expectations for Dianthus Therapeutics, Inc. (DNTH) for FY2025, with the revenue forecasts being adjusted by -8.34% over the past three months. During the same period, the stock price has changed by 9.90%.

Revenue Estimates for FY2025

Revise Downward

-8.34%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+8.42%

In Past 3 Month

Stock Price

Go Up

+9.90%

In Past 3 Month

14 Analyst Rating

Wall Street analysts forecast DNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNTH is 67.25 USD with a low forecast of 44.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

44.00

Averages

67.25

High

100.00

Current: 0.000

Low

44.00

Averages

67.25

High

100.00

Truist

Buy

maintain

$56 -> $63

2026-01-08

New

Reason

Truist

Price Target

$56 -> $63

2026-01-08

New

maintain

Buy

Reason

Truist raised the firm's price target on Dianthus to $63 from $56 and keeps a Buy rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.

H.C. Wainwright

Buy

maintain

$40 -> $47

2025-11-10

Reason

H.C. Wainwright

Price Target

$40 -> $47

2025-11-10

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Dianthus to $47 from $40 and keeps a Buy rating on the shares. The firm sees a "catalyst-rich" 2026 for the company.

Truist

Danielle Brill

Buy

initiated

$56

2025-10-14

Reason

Truist

Danielle Brill

Price Target

$56

2025-10-14

initiated

Buy

Reason

Truist analyst Danielle Brill initiated coverage of Dianthus with a Buy rating and $56 price target. The recent Phase 2 proof-of-concept results with claseprubart in generalized myasthenia gravis were overall supportive of the thesis that Dianthus' differentiated approach to targeting the autoantibody mediated complement cascade may offer similar efficacy as available complement inhibitors, but with a cleaner safety profile, says the analyst, who also thinks the gMG data are relatively de-risking for the ongoing Phase 3 chronic inflammatory demyelinating polyneuropathy trial.

Clear Street

Bill Maughan

initiated

$100

2025-09-16

Reason

Clear Street

Bill Maughan

Price Target

$100

2025-09-16

initiated

Reason

Clear Street analyst Bill Maughan initiated coverage of Dianthus with a Buy rating and $100 price target. Dianthus is a biotech company primarily developing claseprubart for the treatment of complement-driven autoimmune diseases, the analyst tells investors in a research note. The firm believes claseprubart is a \"best-in-class\" complement inhibitor that is well positioned to improve on the standard of care in each of the three indications currently being tested in the clinic. It sees $1B-$2B of sales potential in each of these opportunities.

Wedbush

Outperform

maintain

$42 -> $44

2025-09-12

Reason

Wedbush

Price Target

$42 -> $44

2025-09-12

maintain

Outperform

Reason

Wedbush raised the firm's price target on Dianthus to $44 from $42 and keeps an Outperform rating on the shares. The firm is incorporating the recent $288M secondary offering into its estimates. Wedbush's model also incorporates the over-allotment and while it previously modeled a raise in early 2026, this would appear to be larger in magnitude versus its prior assumptions. With the proceeds from the offering, Dianthus management anticipates cash/equivalents now extend runway into 2028. With Phase 2 MaGiC data in hand, the firm looks ahead to the second half of 2026 for additional top-line readouts from the claseprubart CIDP and MMN programs.

Stifel

Alex Thompson

Buy

maintain

$52 -> $65

2025-09-12

Reason

Stifel

Alex Thompson

Price Target

$52 -> $65

2025-09-12

maintain

Buy

Reason

Stifel analyst Alex Thompson raised the firm's price target on Dianthus to $65 from $52 and keeps a Buy rating on the shares following the positive Phase 2 MaGic trial in AChR+ Myasthenia Gravis. Following the data, the firm's model now reflects higher MG odds of success of 75%, up from a prior 50% forecast, the analyst noted.

Valuation Metrics

The current forward P/E ratio for Dianthus Therapeutics Inc (DNTH.O) is -10.23, compared to its 5-year average forward P/E of -7.79. For a more detailed relative valuation and DCF analysis to assess Dianthus Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.79

Current PE

-10.23

Overvalued PE

-5.10

Undervalued PE

-10.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

441.80

Current PS

1683.31

Overvalued PS

898.56

Undervalued PS

-14.95

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

DNTH News & Events

Events Timeline

No data

News

5.0

01-07Fool

Dianthus CFO Ryan Savitz Sells 20,000 Shares for $903,600

5.0

01-07NASDAQ.COM

Dianthus CFO Ryan Savitz Sells 20,000 Shares for $903,600

9.0

2025-12-23Globenewswire

Dianthus and Leads Biolabs Initiate Phase 1 Trial of LBL-047

People Also Watch

Frequently Asked Questions

What is Dianthus Therapeutics Inc (DNTH) stock price today?

The current price of DNTH is 38.19 USD — it has increased 0.18 % in the last trading day.

What is Dianthus Therapeutics Inc (DNTH)'s business?

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

What is the price predicton of DNTH Stock?

What is Dianthus Therapeutics Inc (DNTH)'s revenue for the last quarter?

Dianthus Therapeutics Inc revenue for the last quarter amounts to 396.00K USD, decreased -81.77 % YoY.

What is Dianthus Therapeutics Inc (DNTH)'s earnings per share (EPS) for the last quarter?

Dianthus Therapeutics Inc. EPS for the last quarter amounts to -0.97 USD, increased 31.08 % YoY.

What changes have occurred in the market's expectations for Dianthus Therapeutics Inc (DNTH)'s fundamentals?

How many employees does Dianthus Therapeutics Inc (DNTH). have?

Dianthus Therapeutics Inc (DNTH) has 78 emplpoyees as of January 10 2026.

What is Dianthus Therapeutics Inc (DNTH) market cap?

Today DNTH has the market capitalization of 1.64B USD.